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Association Screening in the Epidermal Differentiation
Complex (EDC) Identifies an SPRR3 Repeat Number
Variant as a Risk Factor for Eczema
Ingo Marenholz1,2,7, Vladimir A. Gimenez Rivera1,2,7, Jorge Esparza-Gordillo1,2, Anja Bauerfeind2,
Min-Ae Lee-Kirsch3, Andrzej Ciechanowicz4, Michael Kurek5, Tereza Piskackova6, Milan Macek6
and Young-Ae Lee1,2
The genetically determined impairment of the skin barrier is a primary cause of eczema. As numerous genes
essential for an intact epidermis reside within the epidermal differentiation complex (EDC), we screened the
National Center for Biotechnology Information (NCBI) database for putatively functional polymorphisms in the
EDC genes and tested them for association with eczema. We identified 20 polymorphisms with predicted major
impact on protein function. Of these, 4 were validated in 94 eczema patients: a nonsense mutation in FLG2
(rs12568784), a stop codonmutation in LCE1D (rs41268500), a 24-bp deletion in SPRR3 (rs28989168), and a frameshift
mutation in S100A3 (rs11390146). The minor allele frequencies were 15.1, 6.1, 47.2, and 0.4%, respectively. Association
testing of the validated polymorphisms in 555 eczema patients and 375 controls identified a significant effect of
rs28989168 (SPRR3) on eczema. The association was replicated in another 1,314 cases and 1,322 controls, yielding
an overall odds ratio of 1.30 (95% confidence interval 1.12–1.51; P¼ 0.00067) for a dominant mode of inheritance.
Small proline-rich proteins (SPRRs) are crossbridging proteins in the cornified cell envelope (CE), which provides
the main barrier function of stratified squamous epithelia. The SPRR3 variant associated with eczema carried an
extra 24-bp repeat in the central domain, which may alter the physical properties of the CE.
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INTRODUCTION
Eczema (atopic dermatitis) is a chronic inflammatory skin
disease, which is characterized by a defect of the skin barrier
and a dysregulated systemic immune response to common
environmental allergens. In industrialized countries, up to
20% of the children are affected, and family and twin studies
indicated that genetic factors contribute significantly to the
disease (Lichtenstein and Svartengren, 1997; van Beijsterveldt
and Boomsma, 2007). Although the molecular mechanisms
underlying eczema are not fully understood, previous
findings on loss-of-function mutations in the filaggrin gene
(FLG) indicated that the impaired function of the epidermal
barrier is a primary event in the development of eczema
(Palmer et al., 2006).
FLG is located within the epidermal differentiation
complex (EDC), a region of 1.7 Mb on chromosome 1q21.3
comprising over 60 genes, most of which are expressed
during terminal differentiation of the epidermis (Mischke
et al., 1996; Marenholz et al., 2001). The EDC genes
constitute several functionally, structurally, and evolutiona-
rily related gene families, which are important for the
maturation and cornification of the epidermis. They encode
the precursor proteins of the cornified cell envelope (CE),
such as small proline rich proteins (SPRRs) and late cornified
envelope (LCE) proteins, both of which contain short tandem
peptide repeats in the central domain (Hohl et al., 1995;
Marshall et al., 2001). Moreover, they include the family of
fused S100 genes that are characterized by an N-terminal
S100-like calcium-binding domain fused to a large tandem
repeat domain. Members of this family such as filaggrin and
trichohyalin are crosslinked to the CE and serve as a matrix
for the aggregation of keratin intermediate filaments in
terminally differentiating keratinocytes (Presland and Dale,
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2000; Listwan and Rothnagel, 2004). All these structural
genes are flanked by 16 members of the S100 family,
encoding small, calcium-binding S100 proteins, which dis-
play a wide range of inflammatory, immunological, and
antimicrobial activities (Marenholz et al., 2004).
The high degree of relationship among the genes of the
EDC, their coordinated expression, as well as the orche-
strated interaction of the encoded proteins in the formation
of the epidermis suggest that genetic variants in EDC genes
increase susceptibility to eczema similar to the well-
established FLG mutations. Involvement of additional EDC
genes in the pathogenesis of eczema is further supported by
expression analyses that demonstrated dysregulated gene
expression within the EDC region to be associated with the
disease (Sugiura et al., 2005; Esparza-Gordillo et al., 2009;
Guttman-Yassky et al., 2009). Finally, a recent genome-wide
association study has pointed to an eczema risk variant
within the EDC apart from the mutations in FLG (Esparza-
Gordillo et al., 2009). We therefore screened the National
Center for Biotechnology Information (NCBI) single-nucleo-
tide polymorphism (SNP) database for polymorphisms in the
EDC genes that were likely to alter protein function, including
frameshift, nonsense, and stop codon mutations, as well as
small deletions/insertions. Validated polymorphisms were then
tested for association using a case–control study design. Finally,
we demonstrated that a positive association result was not
because of linkage disequilibrium with the FLG mutations.
RESULTS
Screening and validation of polymorphisms in the EDC genes
For the identification of polymorphisms within the EDC
genes, we used the information present in the human NCBI
SNP database (Build 36.3). We restricted our search to
polymorphisms and mutations that are likely to have a major
impact on protein function. Our systematic screening of
the EDC region between S100A10 (chr1:150.222 Mb) and
S100A1 (chr1:151.871 Mb) identified 13 frameshift muta-
tions, 4 nonsense mutations, 2 stop codon mutations, and 1
deletion of 24 bp, which affected a total of 14 EDC genes
(Supplementary Table S1 online). These were distributed over
the entire region and affected members of all gene families of
the EDC. Only for one of the polymorphisms, rs12568784, an
allele frequency was reported in the NCBI SNP database.
We then aimed to verify the polymorphisms in a set of
94 children with eczema from Germany. Only 4 out of 20
variants were validated by sequencing (Supplementary Table
S1 online); the nonsense mutation c.7130A in the filaggrin 2
gene (FLG2; rs12568784), the stop codon mutation p.X115G
in LCE1D, the 24-bp deletion c.196_219del in SPRR3
(rs28989168), which lacks one out of 14 tandem sequence
repeats, and the frameshift mutation c.207delG in S100A3
(rs11390146).
Testing the validated polymorphisms for association with
eczema
Subsequently, the validated polymorphisms were tested for
association in the discovery set, comprising 555 children
with onset of eczema in the first 2 years of life and 375
unselected control individuals from Germany. For
rs28989168 in SPRR3, we found an association of the
insertion variant carrying 14 repeats with eczema yielding
an odds ratio (OR) of 1.25 (95% confidence interval (CI)
1.04–1.50; P¼ 0.020), whereas the polymorphisms in FLG2,
LCE1D, and S100A3 were not associated with eczema
(Table 1). The allele frequencies among the controls were
47.2% for the risk allele in SPRR3, 15.1% for the nonsense
mutation in FLG2, 6.1% for the stop codon mutation in
LCE1D, and 0.4% for the frameshift mutation in S100A3.
Considering the distinct allele frequencies of the validated
polymorphisms and a disease prevalence of 15%, we
estimated the power of the discovery set to detect a potential
effect of the risk variants. Power calculations were performed
under an additive model with different relative risks (RRs) for
the heterozygous (Aa) or homozygous (AA) carriers of the risk
variants (Supplementary Table S2 online). Although the
power of our sample was 97 and 75% to detect a moderate
effect (RRAa¼1.5 and RRAA¼ 2.25) of rs12568784 (FLG2)
and rs41268500 (LCE1D), respectively, the power dropped to
11% for the frameshift mutation in S100A3, which was
because of the low frequency of this allele.
Replicating the association of SPRR3 with eczema
For the replication, we used 1,314 eczema cases with an age
of onset o2 years and 1,322 population-based controls. We
confirmed the association of rs28989168 with eczema,
which we had identified in the discovery set, with a similar
effect size (Table 2). For the combined sample we obtained
an OR of 1.16 (95% CI 1.06–1.27, P¼0.0022). In order to
investigate the mode of inheritance in more detail, we then
calculated the genotype ORs for heterozygous (ORhet) and
homozygous (ORhom) carriers of the risk allele separately.
Heterozygotes and homozygotes yielded similar ORs com-
pared with the noncarriers of the risk allele (Table 3).
Accordingly, our data suggested a dominant mode of
inheritance for the risk allele of SPRR3 in eczema (OR
1.30, 95% CI 1.12–1.51, P¼0.00067).
Table 1. Association between the validated
polymorphisms in the EDC genes and eczema in the
discovery set
Allele
frequency
SNP ID Gene
Minor
allele Eczema Controls
OR
(95% CI) P-value
rs12568784 FLG2 A 13.4% 15.1% 0.87
(0.67–1.14)
0.33
rs41268500 LCE1D G 6.0% 6.1% 0.98
(0.65–1.48)
0.93
rs28989168 SPRR3 14 repeats 52.7% 47.2% 1.25
(1.04–1.50)
0.021
rs11390146 S100A3 del (G) 0.5% 0.4% 1.34
(0.33–5.38)
0.68
Abbreviations: CI, confidence interval; EDC, epidermal differentiation
complex; OR, odds ratio; SNP, single-nucleotide polymorphism.
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Analyzing the FLG mutations as potential confounders on the
eczema risk of rs28989168
Finally, we examined whether the mutations in FLG, which is
also located within the EDC, had an influence on our results.
The FLG mutations are the strongest genetic risk factors for
eczema identified to date and a genome-wide association
study on eczema had indicated strong linkage disequilibrium
between the FLG mutations and polymorphisms located up
to 500 kb away (Esparza-Gordillo et al., 2009). We therefore
included the combined FLG mutations as a cofactor in a
logistic regression analysis. The effect of rs28989168 on
eczema remained significant after adjusting for the combined
FLG mutations (OR 1.23, 95% CI 1.05–1.44, P¼ 0.0086).
DISCUSSION
The EDC in chromosomal region 1q21 harbors 460 genes
that are expressed in the epidermis, and many of them are
crucial for the formation of an intact skin (Mischke et al.,
1996; Marenholz et al., 2001). Recent association and
expression studies pointed to genetic risk factors for eczema
within the EDC region, apart from the well-established FLG
locus (Esparza-Gordillo et al., 2009; Guttman-Yassky et al.,
2009). In a systematic screen for putatively deleterious
mutations in the EDC, we have identified a repeat number
variant in SPRR3 as a, to our knowledge, previously
unreported risk factor for eczema.
We used the information present in the NCBI SNP
database in order to identify polymorphisms in the EDC
genes, which might be disease relevant. Interestingly, out of
20 candidate polymorphisms, only a single one (rs12568784)
had an allele frequency specified in any of the populations of
the HapMap project. In addition, only 4 of the polymorphisms
could be verified in 94 unrelated individuals, although the
probability of finding a genetic variant with an allele fre-
quency of 1% in this sample was 85%. We therefore conclude
that the majority of polymorphisms in the databases without
frequency information are either very rare variants, sequencing
artifacts, or they occur only in discrete populations.
For rs12568784, leading to a frameshift in FLG2, the minor
allele frequency in the discovery set was 15.1%, which was
consistent with the frequency in the CEU HapMap population
of Central European origin. Although the frameshift mutation
in S100A3 (rs11390146) was a rare variant (o1%), the stop
codon mutation in LCE1D (rs41268500), the 24-bp deletion
in SPRR3 (rs28989168), as well as rs12568784 in FLG2 were
common polymorphisms with minor allele frequencies
between 6 and 50%. According to the different allele
frequencies, the power of the discovery set to detect a
moderate RR of 1.5 for eczema ranged from 11% for
rs11390146 to over 97% for rs12568784 and rs28989168.
Consequently, the negative result for rs11390146 (S100A3)
does not exclude an association of this SNP with eczema. In
contrast, an effect of rs41268500 (LCE1D) or rs12568784
(FLG2) on eczema is unlikely. In particular for FLG2, this is a
remarkable finding, as the closely related FLG is the strongest
genetic risk factor for eczema identified to date (Marenholz
et al., 2006; Barker et al., 2007). Although FLG2 has the same
structural organization as FLG, a similar expression pattern
late in epidermal differentiation, and comparable keratin
bundling properties (Listwan and Rothnagel, 2004; Wu et al.,
2009), the consequences of filaggrin 2 dysfunction seem to be
different from filaggrin.
The association of the SPRR3 risk allele with eczema was
confirmed with a similar effect size in a large replication set
comprising 1,314 children with early-onset eczema from
Central Europe and 1,322 population-based controls, indicat-
ing a moderate effect on disease susceptibility. The
rs28989168 polymorphism is located at position 195 of the
coding region in exon 3, in the repeat domain of SPRR3. Four
different alleles (-/C/T/CTGTACCAAGGTCCCTGAGCCAGG)
were assigned to rs28989168 in the SNP database. Our
sequencing results confirmed the presence of two alleles.
One allele was identical to the NCBI Build 36.3 reference
sequence comprising 14 tandem repeats of 24 bp in exon 3 of
SPRR3. The other allele lacked one of the sequence repeats
and corresponded to the alternative sequence HSA243667
(Figure 1). Accordingly, the encoded protein variant com-
prises 13 instead of 14 octapeptide repeats in the central
domain. Obviously, the repeat structure of exon 3 and in
particular identical tandem sequence repeats may lead to
ambiguous SNP annotations in the database. Correspond-
ingly, we did not find a frameshift mutation in SPRR3, which
was reported for rs28989168 in the database.
The eczema-associated variant corresponds to a repeat
number variant in SPRR3 in which the central domain is
expanded by one octapeptide repeat. Accordingly, one
would expect an effect on protein structure and function
Table 2. Association between the SPRR3 variant
rs28989168 and eczema
No. of
individuals
Risk allele
frequency
Set Eczema Controls Eczema Controls OR (95% CI) P-value
Discovery 555 375 52.7% 47.2% 1.25
(1.04–1.50)
0.021
Replication 1,315 1,322 50.5% 47.5% 1.13
(1.01–1.25)
0.033
Combined 1,870 1,697 51.1% 47.5% 1.16
(1.06–1.27)
0.0020
Abbreviations: CI, confidence interval; OR, odds ratio; SPRR3, small
proline-rich protein 3.
Table 3. Mode of inheritance of the SPRR3 variant
rs28989168 in eczema
No. of individuals
Genotype Eczema Controls Genotype OR
13/13 Repeats 442 486
13/14 Repeats 944 812 ORhet (95% CI) 1.28 (1.09–1.50)
14/14 Repeats 484 399 ORhom (95% CI) 1.33 (1.11–1.60)
Abbreviations: CI, confidence interval; ORhet, odds ratio for hetero-
zygotes; ORhom, odds ratio for homozygotes; SPRR3, small proline-rich
protein 3.
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rather than on the gene expression level. Indeed, in a recent
genome-wide mapping study of genetic variants influencing
gene expression levels in normal human skin (n¼ 57), Ding
et al. (2010) did not find significant evidence for SNPs
influencing SPRR3 expression. SPRR3 belongs to a multigene
family, the members of which are expressed in terminally
differentiating keratinocytes of stratified epithelia (Gibbs
et al., 1993; Hohl et al., 1995). SPRRs are crossbridging
proteins of the CE (Steinert et al., 1998a) that provides the
main barrier function in epithelial tissues. CEs of different
epithelia have been shown to vary in their composition of
SPRR proteins correlating with the presumed biomechanic
requirements of a particular epithelium. Therefore, it was
concluded that SPRR proteins serve as modifiers of the tissue-
specific physical properties of the CEs (Steinert et al., 1998b).
SPRR3 is expressed in a variety of stratified squamous
epithelia, mainly in the mucosa of the oral cavity and
esophagus (Hohl et al., 1995). Moreover, it was detected in
neoplastic diseases of the skin such as keratoacanthoma and
squamous cell carcinoma (Heller-Milev et al., 2000). In
genome-wide expression studies on atopic eczema, no
difference in SPRR3 expression was observed between
lesional skin and nonlesional or unaffected skin (Sugiura
et al., 2005; Esparza-Gordillo et al., 2009; Guttman-Yassky
et al., 2009).
Repeat number variants have been described previously
for other structural genes of the EDC like involucrin (IVL) and
FLG (Gan et al., 1990; Simon et al., 1991). A phenotype was
reported for filaggrin, the degradation products of which
serve as natural moisturizing factors of the skin and in which
a reduced number of repeats was associated with dry skin
(Ginger et al., 2005). The repeat number variation in SPRR3
(Figure 1) has not been investigated previously, although it
affected nearly 50% of the alleles in the study populations. In
vitro studies have demonstrated that in contrast to the head
and tail domains, the central repeat domain of SPRR3 was not
involved in the inter- and intra-molecular crosslinking
(Steinert et al., 1999). It was suggested that the central
repeats of the SPRRs serve as highly flexible, crossbridging
spacers in the CE (Steinert et al., 1998a, 1999). Accordingly,
the extra repeat in the eczema-associated variant of SPRR3
might disturb the physical properties of the CE and hence of
the barrier.
In summary, we have identified a repeat number variant in
SPRR3 as a, to our knowledge, previously unreported risk
factor for eczema and replicated this finding in a large
case–control study population. The known function of SPRR3
as a crossbridging protein of the CE in stratified squamous
epithelia may point to an altered barrier function due to the
disease-associated variant. Further studies are required in
order to elucidate the mechanistic role of SPRR3 in eczema.
MATERIALS AND METHODS
Study participants
The physician’s diagnosis of eczema was made according to
standard criteria in the presence of a chronic or chronically
relapsing pruritic dermatitis with the typical morphology and
distribution (Hanifin and Rajka, 1980). In all cases, the age of onset
of eczema was o2 years. The discovery set comprised 555 eczema
patients and 375 controls from Germany. The patients were recruited
at Charite´, Universita¨tsmedizin Berlin, and the controls were blood
donors recruited at the Technical University Dresden. The replica-
tion set comprised 1,314 eczema patients from Germany, Poland,
and the Czech Republic, and 1,322 geographically matched controls
(Esparza-Gordillo et al., 2009). The patients of the replication set
were recruited for the ETAC (Early Treatment of the Atopic Child)
1
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Figure 1. Sequence alignment of the two identified small proline-rich protein 3 (SPRR3) variants. The complete coding sequences of the two SPRR3
alleles and the predicted protein sequences are indicated. The numbering corresponds to the National Center for Biotechnology Information (NCBI) reference
sequence and the reference mRNA NM_001097589, respectively. Tandem sequence repeats are shaded gray. Substitutions of nucleotides on the second
SPRR3 allele, which corresponds to the transcript variant HSA243667, are indicated above the reference sequence, substitutions of amino acids below the
amino-acid sequence. The deletion is indicated by a dashed line. Sequences in italics were used to design primers for amplification of the two different alleles.
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and EPAAC (Early Prevention of Asthma in Atopic Children) trials,
two similar randomized, double-blind, placebo-controlled studies
on the efficacy of levocetirizine and cetirizine, respectively, in the
prevention of asthma (ETAC Study Group, 1998; Hill et al., 2008).
The controls were obtained from blood donation programs in
Prague, Szczecin, and Dresden, respectively. A potential effect due
to population stratification in the replication set has been analyzed
and excluded previously (Esparza-Gordillo et al., 2009).
The study was approved by the institutional ethics review boards
of the participating centers and followed the Declaration of Helsinki
Principles. Written, informed consent was obtained from all patients
or their legal guardians.
Genotyping
Genomic DNA was prepared from whole blood using standard
methods. Functional polymorphisms in the EDC genes identified in
the database were genotyped in 94 randomly selected individuals
with eczema of the discovery set. Genotyping was performed by
sequencing with the BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA), by fluorescence-based semi-
automated allele-sizing using the 3730 DNA Sequence Analyzer
(Applied Biosystems), or by size-separation of the amplified alleles
using agarose gel electrophoresis. All identified variants were
confirmed by sequencing. For each of the analyzed polymorphisms,
primer sequences and annealing temperature for amplification by
PCR as well as the detection method used are indicated in
Supplementary Table S3 online. Validated polymorphisms were
then genotyped in the whole discovery set and if there was
association with eczema, additionally in the replication set. SNPs
rs12568784 and rs41268500 created restriction fragment length
polymorphisms, which were genotyped with the enzymes Tru1I and
AcuI (Fermentas, St Leon-Rot, Germany), respectively. Genotyping
of the four most common loss-of-function mutations in FLG (R501X,
2282del4, R2447X, and S3247X) was performed as described
previously (Palmer et al., 2006; Sandilands et al., 2007). There
was no deviation from Hardy–Weinberg equilibrium for any of the
detected polymorphisms.
Statistical analysis
The Cochran–Armitage trend test was used to test for association
between a polymorphism and eczema. In order to adjust for a
potential effect of the FLG mutations, we performed a logistic
regression analysis including the combined FLG mutations as a
cofactor. The significance of the logistic model was expressed as the
P-value of the likelihood ratio test for the ‘‘full model’’ (with risk
factor and cofactor included) versus the ‘‘null model’’ (with cofactor
only). A P-value of o0.05 was considered statistically significant.
Power calculations were performed under an additive model in the
discovery set with the Genetic Power Calculation software (Purcell
et al., 2003). We estimated the power for three different effect sizes,
by using the allele frequencies identified in the discovery set, a
disease prevalence of 15%, and a type I error rate (a) of 0.05.
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